Atara 安排與 FDA 就 tab-cel CRL 召開 A 型會議

FDA 已安排與 Pierre Fabre 召開 A 型會議，討論 2026 年 1 月 9 日 tab-cel BLA 的 CRL。會議將針對 CRL 各項事項，並探討使用新收集的療效數據重新提交。Atara 預計在 2026 年第二季提供法規更新。

關鍵事實

申報時間: 2026年3月12日下午12:10
事件: 諮詢委員會已排定
方向: 中性
公司: ATRAAtara Biotherapeutics, Inc
資產: tabelecleucel
來源: SEC 8-K
可信度: 有出處

來源摘錄

8-K 0001604464 false 0001604464 2026-03-12 2026-03-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Atara Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36548 46-0920988 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1280 Rancho Conejo Blvd Thousand Oaks , California 91320 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (805) 623-4211 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the

SEC 8-K